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Human embryonic stem cell research has faced a long, tough political battle in the United States. The article
explores the history of this controversy and the motives behind it, leading up to the August 23, 2010 district
court injunction temporarily stopping all U.S. federal funding for research with human ESCs.On August 23, 2010, a United States
(U.S.) district court issued a preliminary
injunction against federal funding of
human embryonic stem cell (hESC)
research, and the international stem cell
community went into shock. The court of
Chief Judge Royce Lamberth ruled in
favor of a suit filed by two researchers
and several activist groups who claimed
that federal funding for hESC research
would harm research on adult stem cells
by increasing competition for limited
federal funding and that federally funded
hESC research involved the destruction
of human embryos, which was prohibited
by law (U.S. District Court for the District
of Columbia, 2010). Research labs across
the U.S. were thrown into confusion about
whether they would be able to continue to
work with hESCs.
The news from Judge Lamberth’s
chambers surprised many people inside
and outside the U.S.; however, it could
be said that the court’s decision was the
culmination of a long battle on research
with embryos that began in the early
1970s. Although there is clear evidence
that almost two-thirds of the U.S. popula-
tion are in favor of hESC research (see,
e.g., http://www.gallup.com/poll/21676/
stem-cell-research.aspx), a vocal minor-
ity has succeeded in slowing and even
stopping this work. How did this minority
viewpoint become so influential? Why do
the critics want to halt hESC research?
There are multiple contributing factors
that make the answer complex, and
subject to interpretation. But what stands
out is how conservative religious groups
in the U.S. have transformed research
with embryos into an ideological battle-
field. Their platform capitalizes on the
persistent failure of government to createa coherent policy strategy in this area.
Decades of political mobilization around
the use of embryos for basic research
and in the context of assisted reproduc-
tion and of research with tissues obtained
from aborted fetuses combined to gen-
erate a U.S. federal policy approach to
hESC research that was reactive instead
of proactive, halting instead of contin-
uous, and selective instead of compre-
hensive. Moreover, the resulting policies
oscillated between contradictory strate-
gies and so were not effective in creating
the social trust necessary for conducting
research in an ethically sensitive area
(Gottweis et al., 2009). The way out of
this situation will be difficult, and no quick
fix will do it. In this Forum, I will present my
perspective of recent historical events
and define a range of strategic issues
that I believe need to be considered while
moving toward securing U.S. federal
funding for hESC research.
History I: The Fetus Battle
Although the historical context can be in-
terpreted in multiple ways, one view
suggests that the politicization of embryo
research in the U.S. is tied to the legaliza-
tion of abortion with the Roe v. Wade U.S.
Supreme Court decision in 1973. Since
then, the political debate over the need
to protect fetuses from harm and destruc-
tion has been used to drive the abortion
fight into the once-separate field of
defining policy to regulate research with
embryos. During the late 1970s and
1980s, much of the debate about re-
search with human reproductive tissues
was focused on fetal material. This fight
culminated in a de facto ban on govern-
ment support for any form of fetal
research from 1988 until 1993. The centralCell Stem Cell 7,argument raised by the critics of fetal
research in the Reagan and George
H.W. Bush administrations was that the
existence of such experimentation might
lead to women being encouraged to
have an abortion because of the potential
benefit to tissue recipients and research
efforts. The restrictions of federal fund-
ing of fetal research reflected the emer-
gence of a contradictory government
strategy that established a clear bound-
ary between public and private medical
research. The central argument in this
context was that the absence of public
consensus regarding the moral status of
the fetus and the embryo precluded both
the development of regulation constrain-
ing such research and the use of public
funds to support it (Khushf, 1997). Thus,
for the U.S., a federal laissez-faire political
approach toward private sector embryo
and fetal research developed, with either
no regulation or only state-level oversight,
and yet a highly restrictive approach
to the federal funding of public sector
efforts. A similar approach was applied
to the field of assisted reproduction. In
other words, at a time when the United
Kingdom’s Warnock committee was
laying groundwork for the 1990 creation
of the Human Fertilization and Embry-
ology Authority (HFEA), which has a
comprehensive regulatory agenda that
includes oversight of public and private
embryo research and in vitro fertiliza-
tion (IVF), no trusted regulatory agency
emerged in the U.S. to address the sensi-
tive issues specific to this biomedical field
and to provide an authoritative voice
when necessary. This inconsistent public
versus private funding approach was
problematic even during the 1980s and
early 1990s, but had dire consequencesNovember 5, 2010 ª2010 Elsevier Inc. 555
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from the late 1990s on, when mammalian
SCNT technology and hESC research
entered the arena. Although federal funds
for many kinds of fetal and embryo re-
search were not available, privately spon-
sored research continued in the absence
of federal guidance or oversight.
The moratorium on federal funding for
research with aborted fetal tissue was
lifted in 1993 by President Bill Clinton in
one of his first actions in office (Vawter,
1993). But gradually, with the advances
in ESC research, fetal research moved
away from the center of attention. Oppo-
nents instead shifted their focus to
research using human embryos, and that
became a central policy issue from the
late 1990s on.
History II: The hESC Controversy
and the War on the ‘‘Culture
of Death’’
In 1993, the U.S. National Institutes of
Health (NIH) formed the Human Embryo
Research Panel (HERP), which set forth
guidelines delineating appropriate and
inappropriate areas of embryo research
(Tauer, 1997). In its report, the panel
made a controversial recommendation,
subsequently rejected by President Clin-
ton, to permit federal funding for the crea-
tion of embryos for certain research
purposes. In other parts of its report,
HERP deemed it acceptable to conduct
research with donated, leftover embryos
from IVF. But before any NIH funding of
research with so-called surplus IVF
embryos could begin, Congress stipu-
lated, via the Department of Health and
Human Services (DHHS) appropriations
process, that any activity involving the
creation of, destruction of, or exposure
to risk of injury or death to human
embryos for research purposes may not
be supported with federal funds (Kinner,
2000). It is this 1996 appropriations bill
rider coauthored by House Republicans
Jay Dickey (Arkansas) and Roger Wicker
(Mississippi) (now called the Dickey-
Wicker amendment) that, 15 years later,
has played a key role in at least tempo-
rarily derailing federally funded hESC
research.
Even with Dickey-Wicker in place, the
story became really stormy after February
1997, when the Scottish announcement
of the birth of the cloned sheep, Dolly,
caused a frenzy of legislative activity in556 Cell Stem Cell 7, November 5, 2010 ª20the U.S. The potential application of
the new cloning technique to humans
received immediate, broad attention. As
soon as February 27, 1997, Missouri
senators Kit Bond and John Ashcroft
introduced the first anticloning bill to the
U.S. Senate, which stated that no federal
funds would be used to finance cloning
research. After the bill failed, President
Clinton sent Congress the Cloning Prohi-
bition Act, but was unable to get it passed.
Many bills to ban cloning followed
these first attempts. Bills that proposed
to ban cloning for both reproductive and
research purposes were countered by
bills that attempted to prohibit cloning
only for creating humans, but that would
permit human SCNT for non-reproductive
efforts. None of these initiatives became
law, and at this time the U.S. still does
not have any legislation covering cloning.
Once again, the extreme polarization
of U.S. opinion in this field has led to
an improvised situation of ‘‘muddling
through,’’ rather than clearly laid out poli-
cies or legislation. In the United Kingdom,
a 2001 law that bans human cloning pre-
cisely differentiates between research-
oriented SCNT and reproductive clon-
ing, but the unsettled legal situation in
the U.S. allowed conservative religious
critics to create foggy, inaccurate associ-
ations between cloning humans, killing
people, aborting fetuses, and hESC
research.
On the political front, there were excel-
lent reasons for the anti-choice move-
ment to shift their focus from abortion to
adopt cloning and hESC research as
a new thematic frontier. Dolly’s birth coin-
cided with a crisis in the movement after
high-profile assassinations of doctors
and clinic staff in Florida, Massachusetts,
and Canada, as well as an escalation of
death, bomb, and anthrax threats and
some actual bombings and arsons.
‘‘Christian patriots’’ and the ‘‘militia move-
ments’’ on the Far Right had begun to
dominate the battle against abortion,
which, with a Democratic, pro-choice
president in power seemed less and less
likely to be won on the legal battlefield.
Influenced by the new papal encyclical,
‘‘Evangelium Vitae’’ of Pope John Paul II
in 1995, more moderate abortion oppo-
nents opted to promote their cause from
a new angle by broadening their agenda.
From the mid 1990s on, campaigns were
launchedaround the idea that a ‘‘culture of10 Elsevier Inc.life’’ must be defended, in opposition to
a ‘‘culture of death,’’ which conservative-
religious groups equated with abortion,
contraception, euthanasia, and hESC re-
search (Chamberlain, 2010). Dolly, SCNT
technology, and hESC research were
therefore under attack by a strategically
redefined anti-choice agenda, in an
attempt to broaden the public appeal of
the argument and therefore gain greater
political influence.
The Politics of Back and Forth
Despite many setbacks, the Clinton
administration did not give up trying to
get a handle on an already highly complex
situation in the stem cell field. With Con-
gress hesitant to fund research involving
human embryos, embryo and IVF re-
search was dependent on private sup-
port. For example, at the end of 1999,
pluripotent stem cell research was only
done in the private sector, with Geron
Corporation supporting key research
groups at the University of Wisconsin
and Johns Hopkins University. Research
that endeavored to create SCNT-derived
human embryos was financed and carried
out by Advanced Cell Technology, a
biotechnology company based in Massa-
chusetts. These forms of private sector
embryo research were increasingly criti-
cized and fueled a continuing debate as
to whether and under what conditions
hESC research should be supported by
the government (Annas et al., 1999). In
response to this debate, the NIH made
an important political move that had
repercussions that continue to be felt
today. They requested a legal opinion
from the general counsel of DHHS, Harriet
Rabb, on whether federal funds could be
used to support research on human
stem cells derived from embryos or fetal
tissue. She concluded that the then-
current law prohibiting the use of DHHS-
appropriated funds for human embryo
research would not apply to research
using stem cells ‘‘because such cells are
not a human embryo within the statutory
definition.’’ Rabb determined that the
statutory ban on human embryo research
defines embryo as an ‘‘organism’’ that
when implanted in the uterus is capable
of becoming a human being. The opinion
stated that pluripotent stem cells are not
and cannot develop into an organism,
as defined in the statute. Furthermore,
Rabb introduced a distinction between
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stem cells from embryos and research
that occurred with those cells after their
removal. In Rabb’s view, federal research
support could be provided as long as
the research did not involve destroying
embryos. DHHS concluded that the NIH
could fund research that uses established
stem cell lines that were derived with pri-
vate funds. But, because of the lan-
guage in the Dickey-Wicker rider, the
NIH could not fund research that, with
federal funds, derived new hESCs from
embryos (Rabb, 1999). This precise legal
interpretation was the foundation for
all federal support of hESC research
throughout the Clinton, George W. Bush
(G.W.B.), and Obama administrations
until August 23, 2010, and Judge Lam-
berth’s ruling.
On August 25, 2000, the NIH published
guidelines for research using human
pluripotent stem cells. At the core of
the new guidelines was a decision to
extend the scope of government sup-
port for hESC research and to create
a framework for regulatory oversight.
Importantly, the new NIH guidelines
permitted the use of cells derived from
spare IVF embryos for research purposes
and constituted a forceful, unambiguous
statement of federal support for hESC
research. However, only a few months
later, the presidential elections and a
new Congress reinitiated the debate
over stem cell research. In a nationally
televised speech on August 9, 2001,
G.W.B. outlined the government’s new
policy that use of federal funds would be
restricted to research on pre-existing
stem cell lines and that an NIH registry
of eligible lines would be created. This
federal pronouncement caused an uproar
in the scientific community and provoked
a series of state level initiatives that
culminated in the passing of California’s
proposition 71, a 2004 referendum that
secured $3 billion USD to support stem
cell research (including hESC research)
over a period of 10 years. Other states,
including Connecticut, Maryland, Massa-
chusetts, and New York, followed suit
with their own large stem cell initiatives.
During the first decade of the 21st
century, NIH funding for hESC research
remained under attack by conservative-
religious forces, but the work continued,
even under the weight of the new funding
restrictions.Prospects
On March 9, 2009, newly elected Presi-
dent Barack Obama issued Executive
Order 13505, ‘‘Removing Barriers to
Responsible Scientific Research Involving
Human Stem Cells.’’ It stated that the
secretary of the DHHS, through the
director of the NIH, may support and
conduct responsible, scientifically worthy
human stem cell research, including using
hESCs. The bulk of the scientific commu-
nity greeted the news with great enthu-
siasm, and predicted a new dawn for
hESC research in the U.S.
These hopes were dashed in August
2010 with the preliminary injunction stop-
ping federal funding of hESC research. In
a key passage of the ruling, Judge Lam-
berth stated that ‘‘ESC research is clearly
research in which an embryo is destroyed.
To conduct ESC research, ESCs must be
derived from an embryo. The process of
deriving ESCs from an embryo results in
the destruction of the embryo. Thus,
ESC research necessarily depends upon
the destruction of a human embryo.
Despite defendants’ attempt to separate
the derivation of ESCs from research on
the ESCs, the two cannot be separated’’
(U.S. District Court for the District of
Columbia, 2010). Furthermore, using
arguably paradoxical reasoning, Lam-
berth wrote that permitting federal fund-
ing of ESC research would increase com-
petition for the NIH’s limited resources
and that a decrease in funding for non-
hESC efforts constitutes an actual, immi-
nent injury, as the plaintiffs had originally
argued. On September 28, 2010, the
U.S. Court of Appeals for the District of
Columbia ruled that the federal financing
of hESC research could continue while
the court considers Lamberth’s decision.
Any decision the court makes will almost
undoubtedly be appealed. Nonetheless,
with the August 2010 court ruling, 10
years of federally funded hESC research
has been at least temporarily halted and
put into doubt.
Regardless of whether or not Congress
revises the Dickey-Wicker amendment
and passes a new law, the strategic
importance of hESC research in the
much broader sociopolitical war of con-
servative-religious groups against the
‘‘culture of death’’ makes it highly unlikely
that the controversy on hESC researchwill
come to an end soon. Stakeholders and
policy makers need to prepare for thisCell Stem Cell 7,development. The political mobilization
around hESC research is aided by a polit-
ical system in which pronounced separa-
tion of powers and related weakness in
political decision making have allowed
the conservative-religious agenda to pen-
etrate deep into the political process with
the aim of targeting and blocking specific
areas of research.
The strict separation of the branches of
U.S. government has many advantages
in a democracy, but is problematic when
highly divisive policies are on the agenda.
At the same time, the field of hESC and
cell nuclear replacement research is
characterized by a failure of government
to comprehensively regulate biomedical
and assisted reproduction research in
the private sector, leading to a regulatory
vacuum that undermines efforts to build
social trust in new and sensitive scien-
tific-medical developments. Comparative
research on hESC policies world-wide
shows that financial support and govern-
ment regulation has not had a smooth
ride anywhere and often caused contro-
versy and political debate (Gottweis
et al., 2009). However, countries such as
the United Kingdom where the govern-
ment took a proactive stance toward
hESC research and developed a com-
prehensive approach combining public
discussion, legislation, and the creation
of trusted regulatory institutions with
broad remits covering public and pri-
vate research (the UK-HFEA model) have
been especially effective at shaping soci-
etal consensus behind hESC research.
For the U.S., these experiences from
abroad imply that, asafirst step,Congress
needs to revise theDickey-Wicker amend-
ment to make clear that it is the will of the
legislature to support hESC research.
But that cannot be the end of the story. I
wouldargue that,with aneyeon the future,
the creation of a regulatory framework that
deals with private and public embryo
research and assisted reproduction will
be essential for creating trust and sustain-
able public support for hESC research.
No single model for such a regulatory
framework exists, and cultural differences
must be considered. However, what is
needed is a systematic, comprehensive,
and proactive policy approach in this field
beyond the quick legal fix so that we can
abandon the muddling-through tactics of
the past that only play into the hands of
the opponents of hESC research.November 5, 2010 ª2010 Elsevier Inc. 557
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